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One of the great scourges of the Victorian era was tuber-
culosis. A huge research effort led to dramatic advances in a
broad range of medical sciences, from epidemiology to
thoracic surgery. Even before treatment was very effective,
sanitoria were established near most large communities,
staffed by doctors, nurses, therapists, and surgeons capable
of delivering a wide range of therapy. Initially, nonpharma-
cological and pharmacological treatments, including digi-
talis (1), were ineffective. The first breakthrough in the
1940s, streptomycin, led to optimism, but hopes were
dashed as the disease evolved and became resistant to
therapy. Subsequently, the development of dual and then
triple therapy overcame the problem of resistance, allowing
the disease to be contained, although not eliminated.
See page 1226
The analogy between tuberculosis and heart failure (HF)
in Western society is striking, but our response to these
epidemics are disparate. Heart failure, just like tuberculosis,
progressed and evolved despite the introduction of single
therapies. Triple-therapy for HF secondary to left ventric-
ular systolic dysfunction has arrived (2), as has the need for
careful monitoring to avoid toxic side effects and for patients
to adhere to relatively complex treatment regimens. A
well-proven series of interventions, each with a relatively
modest benefit (Fig. 1), may reduce two-year mortality
cumulatively by 50% to 60% (Fig. 2) (2). However, heart
failure appears a more complex and recalcitrant condition
than tuberculosis. Most patients with HF require chronic
diuretic therapy and some would consider routine use of
antithrombotic agents, statins, and digoxin, although evi-
dence of a worthwhile benefit for any of these for most
patients is lacking (3–6). There is evidence that implantable
defibrillators, cardiac resynchronization devices, and possi-
bly left ventricular assist systems have an important role for
the management of a substantial minority of patients
(2,7,8). Unfortunately, although a lot of money is spent
treating patients with HF in a haphazard fashion, little
effort has been spent, so far, on organizing infrastructure for
their care.
A city with a population of one million should provide
services to manage at least 10,000 patients with HF, provide
about 140 hospital beds for its management, and expect
about 2,000 to 3,000 new cases each year and about 5,000
admissions (9,10). How then should care for patients with
HF be organized? Disseminating information to all physi-
cians and expecting them all to implement guidelines for the
management of HF is not effective (11–13) because of the
relative complexity of diagnosis and management and be-
cause there are many competing guidelines for other cardi-
ological and noncardiological conditions. Most hospital-
based physicians have already become specialists in some
disease area and most will feel it inappropriate that they
should take the lead in organizing services for patients with
HF (12,13). Primary care physicians could provide the
common investigations required and manage triple therapy,
but by seeking out a large enough number of patients to
acquire the necessary skills and experience, they would
inevitably become specialists. Subspecialization means that
many cardiologists do not have the skills, experience, or
inclination to organize and implement a high standard of
care for patients with HF (14).
Braunstein et al. (15), in this issue of the Journal,
examined the Medicare records of over 100,000 patients age
65 years with HF and examined the effect of noncardiac
comorbidities on outcome over one year. Fifty percent of
patients were age 80 years, 60% were women, only 51%
were reported to have coronary disease, and only 10% were
primarily looked after by a cardiologist, consistent with
previously known data (16–18). It is likely that most
patients had preserved left ventricular systolic function (18).
Sixty-five percent of the patients had one or more hospital-
izations during one-year follow-up, a remarkable statistic in
itself and higher than epidemiological studies (10,17) or
clinical trials have suggested, perhaps reflecting the age of
the patients (10). Forty percent of patients had 5 noncar-
diac comorbidities, and these patients accounted for 80%
of admissions. The most common comorbidities were hy-
pertension (55%), diabetes mellitus (31%), chronic lung
disease (26%), ocular disease (24%), and hypercholesterol-
emia (21%). Only 50% of admissions were thought to be
preventable, of which slightly more than half were for HF.
Many comorbidities were associated with a modest increase
in the risk of preventable admissions and mortality but,
intriguingly, some were associated with a substantially lower
risk, most notably hypercholesterolemia and hypertension.
Excessive attention to comorbidity may impair the treat-
ment of HF (16,19). Braunstein et al. (15) suggest that too
much focus on the management of HF may lead to neglect
of comorbid conditions and that this could be detrimental to
patient care. However, it is far from clear that advice
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proffered by those who are not HF specialists is safe or
effective for patients with HF. There is no specific role for
renal physicians in the management of patients with HF
until dialysis is required. There is no evidence that better
control of glycemia improves the outcome of diabetic
patients with HF. There is no evidence of improved
outcome with specialist care for most patients with chronic
lung disease; only now is the safety and efficacy of steroids
and bronchodilator therapy being tested (20). Likewise,
there is no evidence that mood disorders in patients with
HF respond to conventional therapy, that pharmacological
treatment for depression is safe, or that specialist advice is
more effective than a sympathetic “ear” from a nurse or
doctor (21,22). What is important is to ensure that the
above comorbidities are not used as false excuses for
withholding effective triple therapy given in adequate doses.
Cardiologists also fail to practice evidence-based medi-
cine, are often to blame for unnecessary investigation and
unwarranted polytherapy (23), and have generally failed to
recognize that the relationships between traditional risk
markers for cardiovascular disease, such as hypertension,
hypercholesterolemia, obesity, and cardiovascular morbidity
Figure 1. Effects of therapy on two-year mortality in landmark trials of heart failure of varying symptomatic severity. B beta-blocker; AA aldosterone
antagonist; ACEi angiotensin-converting enzyme inhibitor; NYHANew York Heart Association; Prev. Prevention; Treat. Treatment. CIBIS-II
 Cardiac Insufficiency Bisoprolol Study-part II; CONSENSUS  Cooperative North Scandinavian Enalapril Survival Study; COPERNICUS 
Carvedilol Prospective Randomised Cumulative Survival trial; EPHESUS  Eplerenone’s Neurohormonal Efficacy and Survival Study; MERIT 
Metoprolol CR/XL Randomized Intervention Trial in Heart Failure; RALES  Randomized Aldactone Evaluation Study; SOLVD  Studies Of Left
Ventricular Dysfunction.
Figure 2. The cumulative effects of triple therapy with angiotensin-converting enzyme inhibitors, beta-blockers, and aldosterone antagonists over two years
showing the potential number of lives saved over two years. These studies also showed a reduction in hospitalization and an improvement in patients’
symptoms amongst survivors.
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fail to operate in a conventional manner once patients
develop HF (24). Hypertension is consistently associated
with a better prognosis in patients with HF and provides an
additional substrate for the actions of triple therapy (25).
The lack of evidence for and potential futility or dangers of
aspirin therapy in patients with HF are widely known, yet
cardiologists refuse to give up old habits (3,4). Hypercho-
lesterolemia is also associated with a better outcome either
because it is a marker of an intrinsically better prognosis or
because it provides cardiovascular protection in this setting
(5,6,26). If the former is true, lipid-lowering therapy could
still be an important adjunctive treatment for many patients
with HF and coronary disease. If the latter is true then
lipid-lowering therapy is not only adding to wasteful poly-
therapy but may also have an adverse effect on patient
outcome (5). The large post-infarction trials effectively
excluded HF, as evidenced by the low annual mortality in
these studies (about 2% per annum) (2,27). Three large
studies of statins in patients at increased risk of developing
HF, one in older patients and two in patients with hyper-
tension, showed no effect of statins on mortality or chronic
disability, further suggesting that such treatment may be
futile for patients with HF (2). Two large placebo-
controlled trials examining the effects of statins in over
10,000 patients with HF and coronary disease are now
underway and will provide evidence for the safety and
efficacy of statins (2).
Misuse of pharmacotherapy is not the only or, indeed,
most expensive problem. Many cardiologists recommended
angiography as part of the investigation of HF (28). How-
ever, there is no evidence that revascularization, even for
hibernating or ischemic myocardium, improves patient out-
come; therefore, investigation of coronary disease should
usually be confined to patients with angina intractable to
medical management (29). Two large randomized-
controlled outcome studies are underway investigating the
safety and efficacy of revascularization for patients with HF
(29). Their results should be awaited before jumping to
expensive investigations and potentially deleterious or futile
interventions. For now, there is more evidence in favor of
interventions such as enhanced external counterpulsation
than for angioplasty or coronary bypass grafting in patients
with HF and coronary disease (30,31). There is growing
evidence that a range of implantable devices may be useful
for the management of HF, although the issue of patient
selection to ensure cost-effectiveness is unresolved (32).
Although electrophysiologists may be the most appropriate
specialists to implant devices, it may be more appropriate for
HF physicians to select patients and provide continuing
medical management.
The growing complexity of selecting and monitoring
treatment for HF due to left ventricular systolic dysfunction
means that it is difficult to disseminate best medical practice
to all health professionals who might encounter such pa-
tients. A network of family physicians supported by HF
specialists (possibly recruited from amongst cardiologists,
geriatricians, primary care physicians, or nurses) who could
evaluate new patients, reevaluate them regularly, and man-
age them when they require admission to hospital may be
the most, and possibly only, effective option. The support of
physicians with expertise in the care and rehabilitation of
frail elderly patients will be essential. Depending on the
level of nonspecialist support, a specialist could support a
case-load of 200 to 500 patients. Assuming a prevalence of
HF due to left ventricular systolic dysfunction of 1%, any
community of 20,000 people might require the support of
at least one HF specialist, 20 to 50 such specialists would be
required per million population, translating to between
10,000 to 20,000 specialists in the U.S. or about 1,500 to
3,000 in the UK. The complexity and arguments in favor of
specialist management of left ventricular systolic dysfunc-
tion contrast starkly with the lack of such arguments for
“diastolic” HF, which is equally common but for which a
specialist role is distinctly unproved, so far (33).
Braunstein et al. (15) have highlighted the high preva-
lence and prognostic associations of noncardiac comorbidi-
ties in patients with HF. The study does not provide
information on how these comorbidities should be man-
aged. According to current evidence, it seems more appro-
priate for HF specialists to be educated in the key aspects of
the management of common comorbid medical conditions,
resorting to specialist advice where evidence of real benefit
exists, rather than to try to educate all physicians about how
to manage HF well. The current disorganized state of affairs
in which no group has been allowed to properly champion
the needs of victims of HF, the most common malignant
disease in Europe and North America (34), should not be
allowed to persist. Patients need coordinated services, with
clear management plans that serve their needs and offer
society value-for-money. Too many “cooks” will ensure that
effective policy and management decisions are not made.
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